Does single-dose baloxavir improve symptoms and reduce viral load compared to placebo and oseltamivir in adults and adolescents with uncomplicated influenza?
Single-dose baloxavir is effective for uncomplicated influenza, showing superiority to placebo for symptom alleviation and to oseltamivir for rapid viral load reduction.
Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza. Evidence for the development of decreased susceptibility to baloxavir after treatment was also observed. (Funded by Shionogi; JapicCTI number, 153090, and CAPSTONE-1 ClinicalTrials.gov number, NCT02954354 .).
Hayden et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: